Novavax NVAX, +2.31% reported that a Phase 3 study of its COVID-19 vaccine showed it was 90.4% effective overall. The 29,960-patient study also found that the vaccine provided 100% protection against moderate and severe disease. The company intends to file for regulatory authorizations in the third quarter, and it said it remains on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021. Shares in the Gaithersburg, Md. company jumped 8% in premarket trade.
View Article Origin Here
